TY - JOUR
T1 - Guidelines for the diagnosis and treatment of depressive disorders in China
T2 - The second edition
AU - Feng, Yuan
AU - Xiao, Le
AU - Wang, Wei Wei
AU - Ungvari, Gabor S.
AU - Ng, Chee H.
AU - Wang, Gang
AU - Xiang, Yu Tao
PY - 2019/6/15
Y1 - 2019/6/15
N2 - Background: The recent guidelines for depressive disorders in China are based on both the first edition published in 2003, and new scientific evidence reviewed until the end of 2014. The purpose of the guidelines is to provide a comprehensive overview of the scientific evidence for the diagnosis and treatment of depressive disorders for Chinese patients. Methods: The data used in the guidelines were extracted from the recent literature, and various international treatment guidelines. Results: The current (second) guidelines are based on both evidence-based and measurement-based approaches. Comprehensive and regular assessments with standard instruments are recommended in the acute, continuation, and maintenance treatment phases, and the stage prior to the termination of treatment. In order to reduce the risk of relapse, the new guidelines are extended to the entire course of treatment. Recommendations for pharmacotherapeutic and other treatment modalities are described in detail. Conclusions: Although major advances have been made compared to the 2003 edition of the guidelines, more intensive research is needed to optimize diagnosis and treatment of depressive disorders in China. The new guidelines provide only recommendations for diagnosis and treatment, therefore clinicians should develop individualized treatment plans along the lines of the comprehensive information obtained from patients and their families.
AB - Background: The recent guidelines for depressive disorders in China are based on both the first edition published in 2003, and new scientific evidence reviewed until the end of 2014. The purpose of the guidelines is to provide a comprehensive overview of the scientific evidence for the diagnosis and treatment of depressive disorders for Chinese patients. Methods: The data used in the guidelines were extracted from the recent literature, and various international treatment guidelines. Results: The current (second) guidelines are based on both evidence-based and measurement-based approaches. Comprehensive and regular assessments with standard instruments are recommended in the acute, continuation, and maintenance treatment phases, and the stage prior to the termination of treatment. In order to reduce the risk of relapse, the new guidelines are extended to the entire course of treatment. Recommendations for pharmacotherapeutic and other treatment modalities are described in detail. Conclusions: Although major advances have been made compared to the 2003 edition of the guidelines, more intensive research is needed to optimize diagnosis and treatment of depressive disorders in China. The new guidelines provide only recommendations for diagnosis and treatment, therefore clinicians should develop individualized treatment plans along the lines of the comprehensive information obtained from patients and their families.
KW - China
KW - Depressive disorders
KW - Diagnosis
KW - Treatment
KW - Treatment guidelines
UR - http://www.scopus.com/inward/record.url?scp=85065833171&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2019.04.104
DO - 10.1016/j.jad.2019.04.104
M3 - Review article
C2 - 31078835
AN - SCOPUS:85065833171
SN - 0165-0327
VL - 253
SP - 352
EP - 356
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
ER -